Pharmacyclics to Present at Upcoming Investor Conferences in June

Jun 04, 2010, 13:00 ET from Pharmacyclics, Inc.

SUNNYVALE, Calif., June 4 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced presentations at several investor conferences in June.  

The conference presentation schedule is as follows:

Bank of America Merrill Lynch Smid Cap Conference

Presented by: David Loury, PhD, Chief Scientific Officer

June 9, 2010 at 9:40 a.m. EDT

The Intercontinental Boston, MA


Jefferies 2010 Global Life Sciences Conference

Presented by: Ahmed Hamdy, MD, Chief Medical Officer

June 9, 2010 at 3:00 p.m. EDT

The Grand Hyatt, New York, NY


9th Annual Needham Healthcare Conference

Presented by: David Loury, PhD, Chief Scientific Officer

June 10, 2010 at 10:00 a.m. EDT

The Palace Hotel, New York, NY


ThinkEquity's Mid Year Check-Up on Healthcare Conference

Presented by: Joe Buggy, PhD, Vice President, Research

June 16, 2010 at 10:00 a.m. EDT

The Princeton Club, New York, NY


Piper Jaffray 5th Annual Europe Conference

Presented by: Joe Buggy, PhD, Vice President, Research

June 22, 2010 at 10:30 a.m. BST

Andaz, London, England



A live webcast of the conference presentations will be accessible through a link posted on the investor relations/events & webcasts section of the PCYC website, please go to http://ir.pharmacyclics.com/events.cfm

About Pharmacyclics

Pharmacyclics(R) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. Our mission and goal are worth repeating: to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs. To identify promising product candidates based on exceptional scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate. We exist to make a difference for the better and these are important times to do just that.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.

SOURCE Pharmacyclics, Inc.



RELATED LINKS

http://www.pharmacyclics.com